REALM THERAPEUTICS PLC 23 December 2014(AIM: PURI), an international company focused on safe and effective protection against the spread of infectious pathogens, is pleased to announce the admission of the Company's entire issued share capital comprising 50,135,432 ordinary shares of 10 pence each ("Ordinary Shares") to the AIM market of the London Stock Exchange. Trading in the Company's shares will begin at 8.00 a.m. today. PuriCore's Ordinary Shares have been removed from trading on the Main Market of the London Stock Exchange and their listing on the Official List has been cancelled. The Company's ticker remains PURI.
Information on PuriCore and its business, including that required by AIM Rule 26, can be found on the Company's website: www.puricore.com.
Enquiries:
PuriCore plc | +44 (0) 20 3727 1000 |
Michael Ashton, Chief Executive Officer | |
Marella Thorell, Chief Financial Officer and Chief Operating Officer | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway/Mo Noonan/ Victoria Foster Mitchell | |
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell/ Jen Boorer/ Thomas Smale | |
About PuriCore
PuriCore is an international company focused on developing and commercialising safe and effective products to protect against the spread of infectious pathogens based on its proprietary hypochlorous acid platform technology. Its products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment.In the Supermarket Retail segment, PuriCore offers products to US retailers for use in their fresh produce departments to improve food safety and quality, to extend shelf life and to decrease food wastage. Additionally, the Company's products protect against fungal growth and extend the life of cut flowers, with an initial focus on supermarket floral departments. In Health Sciences, PuriCore's Wound Care business provides products that are used to treat chronic and acute wounds, including diabetic ulcers and burns in humans. A range of products have also been developed to manage wounds in companion and farm animals. The Company's Dermatology business is currently focused on treatments for atopic dermatitis . PuriCore is headquartered in Malvern, Pennsylvania.
To receive additional information on PuriCore, visitwww.puricore.com.
This information is provided by RNS
|
distributed by
|
